CSTL · Castle Biosciences Inc
$34.42
+0.71 (+2.11%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$1.05B
Shares
30.55M
Volume · Oct 9
249.08K
Avg daily vol (3M)
400.56K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.42
Open$33.52
Day$33.39–34.52
52W close$18.15–43.04
Avg vol 30d353K
Short int2.0M · 6.5% float · 4.8d
Short vol40%
Last earningsJul 30, 2026
DataJan 2020–Oct 2026
Filing10-Q · Jul 30
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 2 wks
filed Jul 30, 2026
call held Jul 30, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$357.28M
Trailing 12 months
Net income (TTM)
−$19.41M
Trailing 12 months
Revenue growth YoY
+20.1%
Year over year
Operating margin
-9.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$256.73M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.9%
Year over year · more shares
Price change (1Y)
+45.5%
Trailing year
Short interest
6.5%
Latest settlement · 4.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.8 · calm
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+19%
above
Price vs 50-day avg
+3%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
65%
mid-range
Momentum
relative strength
1-month return
+6%
trailing
6-month return
+37%
trailing
YTD return
−12%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $33 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
5 of 177 funds reported for Sep 30 · net +4.0K sh shares · +1 new
Insider flow
Distributing
Net -$1.6M over 90 days · 100% sells
Short interest
Rising
6.55% of float · ▲ +5.3% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
177 holders — mid 3-yr range
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
Gross margin
15%
expanding
EPS growth
−234%
Y/Y
Free cash flow
$28.3M
Balance sheet
$106.7M
net cash
Quant / Vol
risk profile
Volatility
57%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Jul 30, 2026
Total revenue
· full year 2026
$365M – $375M
prior FY $344.23M
midpoint +7.5% Y/Y
Guided vs delivered
· last 5 settled
Total revenue
full year 2024
guided $275M – $300M
$332.07M
Beat +15.5%
Total revenue
full year 2023
guided at least $200M
$219.79M
In line
Total revenue
2025
guided $255M – $330M
$344.23M
Beat +17.7%
Total revenue
2022
guided $132M – $137M
$137.04M
Beat +1.9%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+19%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $33 › 200d $29 — 50d above 200d
Institutional flow
Accumulating
5 of 177 funds reported for Sep 30 · net +4.0K sh shares · +1 new
Insider flow
Distributing
Net -$1.6M over 90 days · 100% sells
Short interest
Rising
6.55% of float · ▲ +5.3% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
177 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $18
Now $34 · 65%
Range high $43
vs 200-day avg +19%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CSTL
this stock
Castle Biosciences Inc
|
$1.05B | -11.5% | +3.7% | — | 6.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$243.30B | +13.6% | +14.5% | 35.4 | 1.5% |
|
DHR
Danaher Corp /De/
|
$154.52B | -4.0% | +8.5% | 39.0 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.76B | +74.9% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.08B | +25.3% | +6.4% | 33.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CSTL | -3.2% | +6.5% | +36.8% | -3.1% | -11.5% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -4.4% | +4.6% | +26.9% | -5.2% | -25.7% |